14 years of historical data (2011–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Syndax Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.9B | $1.1B | $1.5B | $1.5B | $1.1B | $919M | $268M | $113M | $184M | $105M | — |
| Enterprise Value | $2.1B | $1.3B | $1.2B | $1.5B | $939M | $824M | $244M | $79M | $149M | $81M | — |
| P/E Ratio → | -5.82 | — | — | — | 45.60 | — | — | — | — | — | — |
| P/S Ratio | 79.68 | 47.80 | — | — | 8.16 | 605.60 | 176.47 | 74.43 | 87.26 | 85.92 | — |
| P/B Ratio | 6.45 | 3.93 | 2.74 | 3.31 | 2.79 | 3.64 | 8.47 | 2.13 | 1.76 | 1.25 | — |
| P/FCF | — | — | — | — | 39.30 | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 39.12 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 55.89 | — | — | 6.72 | 543.17 | 160.84 | 52.16 | 70.57 | 66.38 | — |
| EV / EBITDA | — | — | — | — | 35.74 | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | 34.99 | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | 32.37 | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Syndax Pharmaceuticals, Inc. earns an operating margin of -1434.4%. A negative ROE of -75.7% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.5% | 96.5% | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -1434.4% | -1434.4% | — | — | 18.8% | -4708.2% | -3792.9% | -5001.7% | -2939.0% | -3587.4% | -3271.6% |
| Net Profit Margin | -1346.1% | -1346.1% | — | — | 17.8% | -4816.7% | -3688.5% | -4875.5% | -2884.3% | -3645.2% | -3846.7% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -75.7% | -75.7% | -41.0% | -34.1% | 7.5% | -51.5% | -132.2% | -94.0% | -64.5% | -59.0% | -79.1% |
| ROA | -47.7% | -47.7% | -37.7% | -31.5% | 6.6% | -40.1% | -75.9% | -66.9% | -49.4% | -44.7% | -47.0% |
| ROIC | -68.8% | -68.8% | -52.7% | -37.8% | 10.8% | -64.8% | -317.7% | -128.7% | -71.8% | -63.2% | -73.8% |
| ROCE | -57.8% | -57.8% | -45.0% | -33.8% | 7.4% | -43.7% | -101.8% | -80.2% | -56.3% | -47.6% | -46.9% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $192M ($346M total debt minus $154M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.20 | 1.20 | 0.00 | 0.00 | 0.05 | 0.08 | 0.03 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | 0.80 | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.67 | -0.53 | -0.16 | -0.49 | -0.38 | -0.75 | -0.64 | -0.34 | -0.28 | -0.35 |
| Net Debt / EBITDA | — | — | — | — | -7.65 | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | -6.93 | — | — | — | — | — | — |
| Interest Coverage | -68.91 | -68.91 | -1105.55 | -48.38 | 13.81 | -30.30 | — | -39.07 | -43.60 | -45.78 | -13.02 |
Short-term solvency ratios and asset-utilisation metrics
Syndax Pharmaceuticals, Inc.'s current ratio of 5.82x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 16.85x to 5.82x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.82 | 5.82 | 10.00 | 16.85 | 21.68 | 15.84 | 3.39 | 5.18 | 8.45 | 10.47 | 18.16 |
| Quick Ratio | 5.82 | 5.82 | 10.00 | 16.85 | 21.68 | 15.84 | 3.39 | 5.11 | 8.54 | 10.24 | 18.10 |
| Cash Ratio | 5.63 | 5.63 | 9.94 | 16.67 | 21.60 | 15.53 | 3.25 | 5.02 | 8.23 | 10.16 | 18.01 |
| Asset Turnover | — | 0.03 | — | — | 0.31 | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 |
| Inventory Turnover | 2.26 | 2.26 | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 213.81 | — | — | 1.12 | 42.11 | 27.91 | 60.87 | 65.28 | 91.55 | 150.19 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Syndax Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | 2.5% | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 2.2% | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | 2.5% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.5% | — |
| Shares Outstanding | — | $86M | $70M | $61M | $52M | $41M | $30M | $25M | $21M | $15M | $6M |
Compare SNDX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| SNDXYou | $2B | -5.8 | — | — | 96.5% | -1434.4% | -75.7% | -68.8% | — |
| RVMD | $20B | -17.1 | — | — | — | — | -58.1% | -54.3% | — |
| INCY | $20B | 15.8 | 11.9 | 14.8 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
| GMAB | $18B | 15.4 | 14.9 | 15.1 | 95.4% | 31.1% | 23.0% | 22.2% | 0.1 |
| EXEL | $12B | 15.8 | 13.2 | 13.4 | — | 37.6% | 35.5% | 32.1% | 0.2 |
| IBRX | $10B | -15.8 | — | — | 100.0% | -2334.2% | — | — | — |
| MRUS | $7B | -26.9 | — | — | 37.2% | -753.0% | -41.4% | -74.6% | — |
| CELC | $5B | -39.5 | — | — | — | — | -87.5% | -50.3% | — |
| CGON | $5B | -41.7 | — | — | 100.0% | -10067.3% | -19.2% | -26.3% | — |
| ERAS | $4B | -19.8 | — | — | — | — | -43.7% | -39.2% | — |
| IDYA | $3B | -25.2 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 14 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how SNDX stacks up against sector leader Revolution Medicines, Inc..
Start ComparisonSyndax Pharmaceuticals, Inc.'s current P/E ratio is -5.8x. The historical average is 45.6x.
Syndax Pharmaceuticals, Inc.'s return on equity (ROE) is -75.7%. The historical average is -67.6%.
Based on historical data, Syndax Pharmaceuticals, Inc. is trading at a P/E of -5.8x. Compare with industry peers and growth rates for a complete picture.
Syndax Pharmaceuticals, Inc. has 96.5% gross margin and -1434.4% operating margin.